Life history trade-offs in cancer evolution, Nat. Rev. Cancer, vol.13, pp.883-892, 2013. ,
Metronomics: towards personalized chemotherapy?, Nat. Rev. Clin. Oncol, vol.11, pp.413-431, 2014. ,
Spontaneous epigenetic variation in the arabidopsis thaliana methylome, Nature, vol.480, pp.245-249, 2011. ,
Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine, Semin. Canc. Biol, vol.35, pp.53-61, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01195547
Dynamics of targeted cancer therapy, Trends Mol. Med, vol.18, pp.311-316, 2012. ,
Poised epigenetic states and acquired drug resistance in cancer, Nat. Rev. Cancer, vol.14, p.747, 2014. ,
Tumour heterogeneity and the evolution of polyclonal drug resistance, Mol. Oncol, vol.8, pp.1095-1111, 2014. ,
Chemotherapy and the war on cancer, Nat. Rev. Cancer, vol.5, p.65, 2005. ,
The canonical equation of adaptive dynamics: a mathematical view, vol.2, pp.73-83, 2002. ,
URL : https://hal.archives-ouvertes.fr/inria-00164767
Unifying evolutionary dynamics: from individual stochastic processes to macroscopic models, Theor, Popul. Biol, vol.69, pp.297-321, 2006. ,
Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation, Biochim. Biophys. Acta, vol.1860, pp.2627-2645, 2016. ,
Evolutionary dynamics of phenotype-structured populations: from individual-level mechanisms to population-level consequences, Z. angew. Math. Phys, vol.67, pp.1-34, 2016. ,
Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, non-genetic instability and stress-induced adaptation, Cancer Res, vol.75, pp.930-939, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01111271
Tumour heterogeneity and resistance to cancer therapies, Nat. Rev. Clin. Oncol, vol.15, pp.81-94, 2018. ,
Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications, Genome Med, vol.5, p.101, 2013. ,
Chemotherapy dosing schedule influences drug resistance development in ovarian cancer, Mol. Canc. Therapeut, vol.10, pp.1289-1299, 2011. ,
A mathematical model for progression and heterogeneity in colorectal cancer dynamics, Theor, Popul. Biol, vol.79, pp.130-138, 2011. ,
, A mathematical model for the dynamics of cancer hepatocytes under therapeutic actions, J. Theor. Biol, vol.297, pp.88-102, 2012.
Heterogeneity of tumor cells from a single mouse mammary tumor, Cancer Res, vol.38, pp.3174-3181, 1978. ,
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer, Sci. Transl. Med, vol.8, pp.327-351, 2016. ,
De integratione aequationum differentialium, Novi Commentarii Academiae Scientiarum Petropolitanae, vol.8, pp.3-33, 1763. ,
A change of strategy in the war on cancer, Nature, p.508, 2009. ,
, Adaptive therapy, vol.69, pp.4894-4903, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01887358
Mechanisms of cancer drug resistance, Annu. Rev. Med, vol.53, pp.615-627, 2002. ,
Clonal evolution in cancer, Nature, pp.306-313, 2012. ,
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J. Clin. Investig, vol.105, pp.1045-1047, 2000. ,
Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011. ,
Computational approaches and analysis for a spatio-structural-temporal invasive carcinoma model, Bull. Math. Biol, vol.80, pp.701-737, 2018. ,
Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, vol.13, pp.714-726, 2013. ,
Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells, Cancer Metastasis Rev, vol.32, pp.423-448, 2013. ,
Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, vol.501, pp.346-354, 2013. ,
Continuous low-dose therapy with vinblastine and vegf receptor-2 antibody induces sustained tumor regression without overt toxicity, J. Clin. Investig, vol.105, pp.15-24, 2000. ,
Turning ecology and evolution against cancer, Nat. Rev. Cancer, vol.14, pp.371-380, 2014. ,
The role of cell density and intratumoral heterogeneity in multidrug resistance, Cancer Res, vol.73, pp.7168-7175, 2013. ,
, Simplifying the complexity of resistance heterogeneity in metastasis, Trends Mol. Med, vol.20, pp.129-136, 2014.
Finite difference methods for ordinary and partial differential equations: steady-state and time-dependent problems, Society for Industrial and Applied Mathematics (SIAM), 2007. ,
Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations, Biol. Direct, vol.11, pp.1-17, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01355314
Dissecting the dynamics of epigenetic changes in phenotype-structured populations exposed to fluctuating environments, J. Theor. Biol, vol.386, pp.166-176, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01237890
The role of spatial variations of abiotic factors in mediating intratumour phenotypic heterogeneity, J. Theor. Biol, vol.451, pp.101-110, 2018. ,
Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors, Bull. Math. Biol, vol.77, pp.1-22, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-00921266
Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies, ESAIM Math. Model. Numer. Anal, vol.47, pp.377-399, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00714274
Cancer stem cells: the challenges ahead, Nat. Cell Biol, vol.15, pp.338-344, 2013. ,
Cancer as an evolutionary and ecological process, Nat. Rev. Cancer, issue.6, pp.924-935, 2006. ,
Is cell competition relevant to cancer?, Nat. Rev. Cancer, vol.8, pp.141-147, 2008. ,
Clinical overview of metronomic chemotherapy in breast cancer, Nat. Rev. Clin. Oncol, vol.12, pp.631-644, 2015. ,
Cancer genomics: one cell at a time, Genome Biol, vol.15, p.452, 2014. ,
Numerical optimization, 1999. ,
The clonal evolution of tumor cell populations, Science, vol.194, pp.23-28, 1976. ,
On the meaning of the word 'epimutation, Trends Genet, vol.30, pp.519-520, 2014. ,
Combination of direct methods and homotopy in numerical optimal control: Application to the optimization of chemotherapy in cancer, J. Optim. Theor. Appl, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01568779
Inferring fitness landscapes by regression produces biased estimates of epistasis, Proc. Natl. Acad. Sci. U.S.A, vol.111, pp.2301-2309, 2014. ,
Transport equations in biology, 2006. ,
Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments, Transl. Oncol, vol.1, pp.158-164, 2008. ,
Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'what does not kill me strengthens me, Br. J. Cancer, vol.112, pp.1725-1732, 2015. ,
Nondarwinian dynamics in therapy-induced cancer drug resistance, Nat. Commun, vol.4, p.2467, 2013. ,
Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy, J. Math. Pures Appl, vol.116, pp.268-308, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01416594
The genetic/non-genetic duality of drug 'resistance'in cancer, Trends Cancer, vol.4, pp.110-118, 2018. ,
Why does cytotoxic chemotherapy cure only some cancers?, Nat. Clin. Pract. Oncol, vol.6, pp.43-52, 2009. ,
Metronomic chemotherapy: changing the paradigm that more is better, Curr. Oncol, vol.16, pp.7-15, 2009. ,
Optimal control for mathematical models of cancer therapies, 2015. ,
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, pp.69-80, 2010. ,
Handbook of cancer chemotherapy, 2011. ,
A phenotype-structured individual-based model for the evolution of cancer cell populations under chemotherapy, 2019. ,
Reversible and adaptive resistance to braf (v600e) inhibition in melanoma, Nature, vol.508, pp.118-122, 2014. ,
Cell competition and its implications for development and cancer, J. Genet. Genomics, vol.38, pp.483-495, 2011. ,
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, pp.251-255, 2013. ,
Genetic heterogeneity and cancer drug resistance, Lancet Oncol, vol.13, pp.178-185, 2012. ,
Competitive cell interactions in cancer: a cellular tug of war, Trends Cell Biol, vol.23, pp.160-167, 2013. ,
, We can obtain from equation (B.15) an explicit solution for µ i (t) when f i (0) < H i : µ i (t) = ? i + ? i (µ i